ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ELOX / insiders
INKT (36) KLRS (30) GRML (29) LONA (35) ⌘ Pro Terminal β†’

Eloxx Pharmaceuticals Inc. (ELOX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$12.84 -4.53% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.71

Eloxx Pharmaceuticals Inc. (ELOX) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $54.3M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ELOX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ELOX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $12.84 (-4.53% 1D, market cap $54.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ELOX compare to INKT and KLRS in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELOX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, INKT (MiNK Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $53.7M) and KLRS (Kalaris Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $48.3M). Among the 5-stock peer group, ELOX leads on earnings multiple (N/A) while ELOX leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ELOX?
β–Ό

Per ELOX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001035354), Eloxx Pharmaceuticals Inc. generated $18.0M in revenue (+183.5% YoY), -$6.0M in net income, and -$6.3M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $12.71 (-1.01%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (32/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510032
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (6)Whales (6)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
$25 Bull$11 Base$9 Bear
πŸ“¬ FREE ELOX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ELOX)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
πŸ” WHY ELOX SCORES 32/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 1/9

β–² #2 Bullish Driver: Macro Regime Fit+7/20 pts (22% of score)

FRED Regime Γ— Technicals: 31% of 52W Range β€’ RSI-14 at 45.4 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
40
Grade D$13.89-10% Next Q
Q2 (-2Q)
37
Grade E$12.50+5.4% Next Q
Q3 (-1Q)
35
Grade E$13.17-2.5% Next Q
Current
32
Grade E$12.84-9.2% Hist 90D Ξ±
Trajectory: D (40) β†’ E (32)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ELOX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ELOX currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.19) and Max Pain ($13.48) forces dealer call-delta covering toward $24.57.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELOXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œELOX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

ELOX Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ELOX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ELOX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELOX)

  • βœ“Walkthrough of ELOX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ELOX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +16.62%πŸ“ HORIZONTAL RANGE
2026-11-03O $13.20H $13.45L $12.84C $12.84VOL 14.0K
RES: $29.68SUP: $11.26SMA50: $15.19SMA200: $14.68
$24.46$20.06$15.65$11.24$6.83RES $29.68SUP $11.26$12.842026-06-092026-07-162026-08-202026-09-252026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELOX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ELOX Butterfly Map β†’ + Track ELOX β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +183.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ELOX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ELOX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ELOX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELOX)

Health Care Rank #728 of 1015 βš”οΈ INKT vs ELOX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ELOX vs. INKT, KLRS, GRML, LONA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Eloxx Pharmaceuticals Inc. (ELOX) ranks #728 by composite RQD confidence (32/100, grade E) and #729 by equity capitalization ($54.3M). Within this direct 5-issuer industry benchmark cohort, ELOX leads on earnings valuation at N/A trailing P/E, while ELOX leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. INKT currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with ELOX at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ELOX ACTIVE
Eloxx Pharmaceuticals Inc.
E 32/100 β€” β€” -35.0% -4.53% $54.3M Benchmark Subject
INKT
MiNK Therapeutics Inc.
D- 36/100 β€” β€” -35.0% +4.84% $53.7M /inkt-vs-elox β†’
KLRS
Kalaris Therapeutics Inc.
E 30/100 β€” β€” -35.0% -1.48% $48.3M /klrs-vs-elox β†’
GRML
Greenland Mines Ltd.
E 29/100 β€” β€” -35.0% -12.88% $62.7M /grml-vs-elox β†’
LONA
LeonaBio Inc.
D- 35/100 β€” β€” -35.0% -4.25% $46.5M /lona-vs-elox β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001035354 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eloxx Pharmaceuticals Inc. (ELOX) reported GAAP revenue of $18.0M (+183.5% vs. FY2024 revenue of $6.4M , and -62.8% cumulative change since FY2023) , GAAP net income of -$6.0M, operating cash flow of -$6.3M, and free cash flow of -$6.3M (-34.2% YoY). On the balance sheet, ELOX closed FY2025 with $5.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $18.0M -$6.0M -$6.3M -$6.3M $5.3M $0
FY2024 (FY) 2024-12-31 $6.4M -$3.1M -$4.7M -$4.7M $3.0M $0
FY2023 (FY) 2023-12-31 $48.4M -$17.1M -$14.3M -$14.3M β€” β€”

3. ELOX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELOX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $12.84 (-4.53% 1D, market cap $54.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does ELOX compare to INKT and KLRS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELOX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, INKT (MiNK Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $53.7M) and KLRS (Kalaris Therapeutics Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $48.3M). Among the 5-stock peer group, ELOX leads on earnings multiple (N/A) while ELOX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ELOX?

Per ELOX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001035354), Eloxx Pharmaceuticals Inc. generated $18.0M in revenue (+183.5% YoY), -$6.0M in net income, and -$6.3M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ELOX trading relative to its 50-day, 200-day, and 52-week technical levels?

ELOX last traded at $12.84 (-4.53% on volume of 59,870 shares), positioning the stock -15.47% below its 50-day simple moving average ($15.19) and -12.53% below its 200-day simple moving average ($14.68). Across its 52-week range of $8.20 to $23.40, ELOX sits at the 30.5% percentile with a 14-day RSI of 45.4 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($11.24 to $14.44).

Direct Sub-Reports: ELOX RQD Cockpit ELOX 12M Forecast ELOX Earnings & Move ELOX Dividends & DRIP ELOX Insiders & 13F ELOX Whale Options ELOX Profit Sankey ELOX News & Why
ROARABLE RATING BRIEF β€’ RQD 32/100 (E) βœ“ SEC XBRL & RQD VERIFIED

ELOX β€” Eloxx Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Eloxx Pharmaceuticals Inc. (ELOX) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $12.84 (-4.53% 1D, market capitalization $54.3M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of -11.87%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Eloxx Pharmaceuticals Inc. (ELOX) is listed on NASDAQ in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The market capitalization is $0.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Eloxx Pharmaceuticals Inc. (ELOX) reported $18.0M in annual revenue (up from $6.4M in FY2024, +183.5% YoY) and -$6.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($48.4M revenue, -$17.1M net income) through FY2025, ELOX scaled operating cash flow to -$6.3M and free cash flow to -$6.3M, backed by $5.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -11.87% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $8.20 – $23.40 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), ELOX carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can ELOX sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $18.0M and free cash flow of -$6.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ELOX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ELOX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Eloxx Pharmaceuticals Inc. (ELOX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ELOX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ELOX Bull vs. Bear Conversation Board β€” What's Your Call at $12.84?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ELOX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ELOX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER β€’ Swing & Catalyst Trader πŸ‚ BULLISH 🎯 Target: $17.75 (+32.0%)
πŸ“Œ Pinned Debate

Cash on hand of $4.8M against zero reported debt in FY 2025 gives the company a balance sheet without leverage pressure.

Long ELOX at $13.45 targeting $17.75. Cash on hand of $4.8M against zero reported debt in FY 2025 gives the company a balance sheet without leverage pressure.. Institutional whale score is 6/20 and the risk/reward vs. the $8.20 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd πŸ‚ BULL

@BreakoutHunter Agree on the RQD 32/100 quality, though with 1.0 beta I'm scaling in with half-size at $13.45 and keeping dry powder in case we test $12.51.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $10.09 (-25.0%)
Spot @ $13.45

ROIC of -35% and FCF yield of -11.87% show the business is consuming cash with no revenue in FY 2025.

Here is the bear case nobody on the bull side wants to address on ELOX: ROIC of -35% and FCF yield of -11.87% show the business is consuming cash with no revenue in FY 2025.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.

LIVE TAPE